Robert Chess

Robert Chess, Director at Nektar Therapeutics (NASDAQ:NKTR), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Robert Chess purchased 18,279 Nektar Therapeutics...